Communication of the meeting of Transparency Council No. 32/2025 on 28 July 2025 with resolutions
We invite you to read minutes of the meeting of Transparency Council No. 32/2025 on 28 July 2025 during which the following resolutions were adopted:
- At its meeting on 28 July 2025, the Transparency Council adopted position No. 97/2025 on the eligibility of the healthcare service “Robotic thoracic surgery (lung cancer and other thoracic cancers)” as a guaranteed service – in relation to the indication: cancer of uncertain or unknown nature of the middle ear, respiratory organs and chest (ICD-10 D38);
- At its meeting on 28 July 2025, the Transparency Council adopted position No. 98/2025 on the appraisal of drug Elmiron (pentosan polysulfate sodium) under the drug program “Treatment of painful bladder syndrome with glomerular changes or Hunner’s lesions, interstitial cystitis (ICD-10 N 30.1)”
- At its meeting on 28 July 2025, the Transparency Council adopted position No. 99/2025 on tha appraisal of drug Abecma ( idecabtagene vicleucel) under drug program B.54. “Treatment of patients with plasma cell myeloma (ICD-10: C90.0)”;
- At its meeting on 28 July 2025, the Transparency Council adopted position No. 100/2025 on tha appraisal of drug Staloral 300 (mixtures of allergen extracts) for the indication: treatment of allergic rhinitis;
- At its meeting on 28 July 2025, the Transparency Council adopted position No. 101/2025 on the appraisal of drug Breyanzi (lisocabtagene maraleucel) under the drug program “Treatment of patients with B-cell lymphomas (ICD 10: C82, C83, C85)”;
- At its meeting on 28 July 2025, the Transparency Council adopted opinion No. 130/2025 on the inclusion of medicinal products containing the active substances nivolumab + ipilimumab in the scope of indications for use or dosage, or method of administration other than those specified in the Summary of Product Characteristics, i.e. “Treatment of patients with melanoma of the skin or mucous membranes (ICD-10: C43)”;
- At its meeting on 28 July 2025, the Transparency Council adopted opinion No. 131/2025 on the inclusion of medicinal products containing the active substance entecavirum in the scope of indications for use or dosage, or method of administration other than those specified in the Summary of Product Characteristics, i.e. prevention of hepatitis B virus reactivation;
- At its meeting on 28 July 2025, the Transparency Council adopted opinion No. 132/2025 on the inclusion of medicinal products containing the active substance tenofovir disoproxil in the scope of indications for use or dosage, or method of administration other than those specified in the Summary of Product Characteristics, i.e. prevention of hepatitis B virus reactivation.